METHOD OF TREATING RECTAL CANCER Russian patent published in 2013 - IPC A61N5/02 A61N5/10 A61K31/10 A61K31/417 A61K31/7068 A61K31/734 A61P35/00 A61B17/02 A61M31/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly oncology and surgery, and may be used in treating rectal cancer. That is ensured by teleirradiation, oral administration of capecitabine, intrarectal administration of metronidazole, local SHF hyperthermia followed by a surgical intervention. Capecitabine is administered 2000 mg/m² from the 1^st to 14^th days. Metronidazole 10 g/m² is intrarectally administered on the 3^rd and 5^th therapeutic days as a part of a composite mixture having the following proportions, wt %: metronidazole 12-22, sodium alginate 4-6, dimethylsulphoxide 2, distilled water up to 100. The 5-hour exposure of metronidazole is followed by a session of teletherapy. The local SHF hyperthermia at temperature 41-45° for one hour follows a session of teletherapy on 3^rd, 4^th and 5^th therapeutic days. The surgical intervention is conducted 4 weeks after the completion of the preoperative therapy.

EFFECT: method provides ensuring complete therapeutic pathomorphism of the tumour in 25% of patients, reducing toxic and post-therapeutic complications, as well as enables conducting sphincter-preserving surgical interventions.

3 ex